Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2018-05-10 Investor Presentation
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Investor Presentation - May 2018 8 pages 1.5MB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation May 2018' and contains detailed slides about the company's business, technology platform, validation studies, milestones, and investment highlights. It is structured as a presentation with multiple slides, images, and explanatory text aimed at investors. There is no indication of it being a formal financial report, regulatory filing, or announcement of voting results. The content focuses on business strategy, technology, and investment rationale, which aligns with the definition of an Investor Presentation (IP). The document length is 7,356 characters, which is consistent with a detailed presentation rather than a brief announcement or a full annual report. Therefore, the appropriate classification is Investor Presentation (IP).
2018-05-10 English
Appendix 3B 12 pages 281.9KB
Share Issue/Capital Change Classification · 100% confidence The document is an ASX announcement titled 'Appendix 3B' dated 3 May 2018 from Phylogica Limited. It details the cancellation of unlisted options and provides information about the securities issued or to be issued, including exercise prices and expiry dates. The document is a formal notification to the ASX regarding changes in the company's securities, specifically the cancellation of options upon the resignation of a director. It does not contain financial statements, management discussion, or detailed financial results. It is not a report but an announcement related to capital changes, specifically about securities issuance and cancellation. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is substantial (15,000 characters), and it is not merely a brief notice or a certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA).
2018-05-02 English
Trading Policy 8 pages 85.6KB
Director's Dealing Classification · 95% confidence The document is an ASX announcement dated 3 May 2018, titled 'Trading Policy'. It details the company's internal policy on trading securities by Key Management Personnel, including definitions, prohibitions on insider trading, trading windows, approval and notification requirements, and exceptions. The content is a policy document rather than a financial report, earnings release, or regulatory filing. It does not contain financial statements, audit information, or voting results. It is not a report publication announcement since it is the full policy text, not a notice about a report. The document relates to internal governance and compliance rules regarding securities trading by insiders. Therefore, the most appropriate classification is Director's Dealing (DIRS), as it concerns rules and disclosures related to directors and key management personnel trading company shares.
2018-05-02 English
Final Director's Interest Notice 3 pages 184.0KB
Director's Dealing Classification · 100% confidence The document is an ASX announcement titled 'Appendix 3Z Final Director’s Interest Notice' relating to a final director's interest for Ms Stephanie Unwin. It details the director's relevant interests in securities and confirms the director ceased to be a director on 27 April 2018. The document is short (3704 characters) and focuses on reporting a director's personal share transactions and interests. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives. There is no financial report or broader company performance data, so it is not an Annual Report or Earnings Release. It is not a regulatory filing or announcement of a report but a direct disclosure of director share interests.
2018-05-01 English
March 2018 Operational Update and Cashflow 11 pages 247.1KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Operational update – March Quarter' and provides detailed information about company activities during the March quarter, including changes to the board and management, scientific platform development, and a quarterly cash flow statement (Appendix 4C) with financial data for the quarter ended 31 March 2018. It includes substantive financial data and analysis for a period shorter than a full fiscal year, consistent with a quarterly report. The document also invites shareholders to a conference call to discuss the quarter's activities. There is no indication that this is a full annual report or just an announcement of a report. The presence of detailed financial statements and operational updates aligns with the definition of an Interim / Quarterly Report (IR). Q1 2018
2018-04-29 English
March Quarter Investor Call Details 2 pages 94.2KB
Call Transcript Classification · 85% confidence The document is an ASX announcement inviting shareholders and interested parties to join a conference call regarding the operational update for the March quarter. It provides details about the conference call, including date, time, and dial-in numbers, and mentions a Q&A session. The document also references an Appendix 4C Quarterly report but does not contain substantive financial data or the report itself. The length is 3891 characters, which is relatively short and consistent with an announcement rather than a full report. There is no detailed financial analysis or statements included, only an invitation to a call discussing the quarter's operations. Therefore, this document is best classified as a Call Transcript (CT) announcement or invitation, but since it is not the transcript itself, it is more accurately a Regulatory Filing (RNS) as a general announcement. However, given the specific nature of the content focusing on the conference call for the quarterly operational update, the best fit is Call Transcript (CT) category, as it relates directly to the earnings/operational call event.
2018-04-29 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.